The findings indicate that the currently approved 600-mg dose of intravenous ocrelizumab is optimal to significantly slow ...

Rituximab, a lower-cost treatment, may be as effective at managing RRMS as the approved therapy Ocrevus, a new study from ...

One in three women diagnosed with MS will subsequently conceive, therefore consideration of the maternal-infant dyad is ...

The study aimed to determine whether treatment with high dose ocrelizumab would provide an additional benefit in slowing disability progression.

Findings confirmed the approved 600mg IV dose was optimal for slowing disability progression in relapsing MS. A phase 3 study evaluating a higher dose of ocrelizumab in adults with relapsing ...

The following is a summary of “Recall vaccination increases detectable B-cell reactivity in persons with multiple sclerosis treated with ocrelizumab,” published in the April 2025 issue of Journal of ...

In the Phase III MUSETTE study, a higher dose of intravenous Ocrevus (ocrelizumab) did not provide additional benefit in ...

Roche Holdings AG (OTC:RHHBY) on Wednesday announced data from MUSETTE Phase 3 trial of a high dose of Ocrevus (ocrelizumab) intravenous (IV) infusion in adult patients with relapsing multiple ...

Neuro-immunologist Stephen Hauser, MD, whose maverick thinking transformed the treatment landscape for patients with multiple ...

Tolebrutinib, a brain-penetrant BTK inhibitor, may fill a significant unmet need by delaying disability progression in patients with non-relapsing secondary progressive multiple sclerosis.

Neurologist Stephen Hauser, MD, of the University of California San Francisco, and epidemiology professor Alberto Ascherio, ...